PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.56
+0.01 (+0.20%)
As of 12:10PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.55
Open2.55
Bid2.55 x 3100
Ask2.56 x 1000
Day's Range2.46 - 2.56
52 Week Range2.25 - 3.55
Volume365,967
Avg. Volume1,277,106
Market Cap371.497M
Beta (3Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-02
1y Target Est3.00
Trade prices are not sourced from all markets
  • PDL BioPharma Names Edward Imbrogno Vice President of Finance
    PR Newswire8 days ago

    PDL BioPharma Names Edward Imbrogno Vice President of Finance

    INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. ...

  • PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
    PR Newswire20 days ago

    PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • PDL BioPharma Announces New $100 Million Stock Repurchase Program
    PR Newswire22 days ago

    PDL BioPharma Announces New $100 Million Stock Repurchase Program

    INCLINE VILLAGE, Nev., Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission. "We believe this program is an appropriate means to create shareholder value given the current discrepancy between our share price and our book value," said John McLaughlin, Chief Executive Officer of PDL. The timing of purchases and the number of shares repurchased under the new program by PDL will depend on a variety of factors including price, trading volume, corporate and regulatory requirements and market conditions.  Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when PDL might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.

  • Is PDL BioPharma (PDLI) a Great Stock for Value Investors?
    Zacks25 days ago

    Is PDL BioPharma (PDLI) a Great Stock for Value Investors?

    Is PDL BioPharma (PDLI) a great pick from the value investor's perspective right now? Read on to know more.

  • The 7 Best Biotech Stocks for Investors Who Hate Risk
    Kiplinger26 days ago

    The 7 Best Biotech Stocks for Investors Who Hate Risk

    Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)

  • PR Newswire26 days ago

    SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma

    Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value Believes the PDL Board Must Pursue Alternative Capital Allocation Strategies, Including ...

  • Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?
    Zackslast month

    Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?

    PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • 3 Top Stocks Under $10
    Motley Foollast month

    3 Top Stocks Under $10

    These low-priced stocks could generate high returns.

  • PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Parker Drilling, CoreLogic, Steven Madden, Diebold Nixdorf, Nevro, and PDL BioPharma — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Parker ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PDLI earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 PDL BioPharma Inc Earnings Call

  • PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
    Zacks2 months ago

    PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

    PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

  • Associated Press2 months ago

    PDL BioPharma: 2Q Earnings Snapshot

    The Incline Village, Nevada-based company said it had a loss of 76 cents per share. Earnings, adjusted for one-time gains and costs, were 10 cents per share. The biotechnology company posted revenue of ...

  • PDL BioPharma Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    PDL BioPharma Reports Second Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, ...

  • ACCESSWIRE2 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
    PR Newswire2 months ago

    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

    INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") ...

  • PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018
    PR Newswire2 months ago

    PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018

    INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial ...

  • ACCESSWIRE3 months ago

    Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on PIRS sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Pacific Biosciences of California Inc. (NASDAQ: PACB), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).

  • Is PDL BioPharma (PDLI) a Great Stock for Value Investors?
    Zacks3 months ago

    Is PDL BioPharma (PDLI) a Great Stock for Value Investors?

    Let's see if PDL BioPharma, Inc. (PDLI)stock is a good choice for value-oriented investors right now from multiple angles.

  • Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors
    PR Newswire4 months ago

    Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth ...

  • Shlomo Yanai Elected to PDL BioPharma's Board of Directors
    PR Newswire4 months ago

    Shlomo Yanai Elected to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 11, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June ...

  • 4 ‘Fixer Upper’ Stocks Poised to Bounce Back
    InvestorPlace4 months ago

    4 ‘Fixer Upper’ Stocks Poised to Bounce Back

    Changing industry dynamics, excessive debt levels or poor management decisions can take even the largest of companies to a breaking point. Because they’ve faced hardships that weighed on their share prices, we define fixer uppers as stocks of $5 per share or less. By making wise investments in troubled companies, however, even small investors can sometimes finish rich with fixer-upper stocks.

  • PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
    PR Newswire5 months ago

    PDL BioPharma Names Dr. Jill Jene Vice President, Business Development

    INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet. "Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products.